Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set

Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, Hungria V, Engelhardt M, Gay F, Feria AG, Oliva S, Oostvogels R, Gozzetti A, Rosenbaum C, Kumar S, Stadtmauer EA, Einsele H, Beksac M, Weisel K, Anderson KC, Mateos MV, Moreau P, San-Miguel J, Munshi NC, Avet-Loiseau H (2020)

Publication Type: Journal article

Publication year: 2020

Journal

Book Volume: 136

Pages Range: 3033-3040

Journal Issue: 26

DOI: 10.1182/blood.2020008150

Abstract

The primary cause of morbidity and mortality in patients with multiple myeloma (MM) is an infection. Therefore, there is great concern about susceptibility to the outcome of COVID-19-infected patients with MM. This retrospective study describes the baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International Myeloma Society to understand the initial challenges faced by myeloma patients during the COVID-19 pandemic. Analyses were performed for hospitalized MM patients. Among hospitalized patients, the median age was 69 years, and nearly all patients (96%) had MM. Approximately 36% were recently diagnosed (2019-2020), and 54% of patients were receiving first-line therapy. Thirty-three percent of patients have died, with significant geographic variability, ranging from 27% to 57% of hospitalized patients. Univariate analysis identified age, International Staging System stage 3 (ISS3), high-risk disease, renal disease, suboptimal myeloma control (active or progressive disease), and 1 or more comorbidities as risk factors for higher rates of death. Neither history of transplant, including within a year of COVID-19 diagnosis, nor other anti-MM treatments were associated with outcomes. Multivariate analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained independent predictors of adverse outcome with COVID-19 infection. The management of MM in the era of COVID-19 requires careful consideration of patient- and disease-related factors to decrease the risk of acquiring COVID-19 infection, while not compromising disease control through appropriate MM treatment. This study provides initial data to develop recommendations for the management of MM patients with COVID-19 infection.

Involved external institutions

Icahn School of Medicine at Mount Sinai United States (USA) (US) Dana–Farber Cancer Institute United States (USA) (US) Hospital Universitario 12 de Octubre Spain (ES) University of Leeds United Kingdom (GB) Hackensack University Medical Center (HUMC) United States (USA) (US) University College London Hospitals (UCLH) United Kingdom (GB) Clinica São Germano Brazil (BR) Albert-Ludwigs-Universität Freiburg Germany (DE) University of Turin / Università degli Studi di Torino (UNITO) Italy (IT) Manises Hospital Spain (ES) Paracelsus-Elena-Klinik Kassel Germany (DE) Università degli Studi di Siena (UNISI) / University of Siena Italy (IT) New York Presbyterian Hospital United States (USA) (US) Mayo Clinic United States (USA) (US) University of Pennsylvania United States (USA) (US) Ankara University / Ankara Üniversitesi Turkey (TR) Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) University of Salamanca / Universidad de Salamanca Spain (ES) Nantes University Hospital / Centre hospitalier universitaire de Nantes (CHU) France (FR) Universidad de Navarra Spain (ES) Intergroupe Francophone du Myélome (IFM) France (FR) Universitätsklinikum Würzburg Germany (DE)

How to cite

APA:

Chari, A., Samur, M.K., Martinez-Lopez, J., Cook, G., Biran, N., Yong, K.,... Avet-Loiseau, H. (2020). Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set. Blood, 136(26), 3033-3040. https://doi.org/10.1182/blood.2020008150

MLA:

Chari, Ajai, et al. "Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set." Blood 136.26 (2020): 3033-3040.

BibTeX: Download